Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS
Condition(s):Myelodysplastic SyndromesLast Updated:February 16, 2023Suspended
Hide Studies Not Open or Pending
Condition(s):Myelodysplastic SyndromesLast Updated:February 16, 2023Suspended
Condition(s):Chronic Myelomonocytic LeukemiaLast Updated:March 7, 2024Withdrawn
Condition(s):Acute Myeloid LeukemiaLast Updated:August 7, 2023Active, not recruiting
Condition(s):Brain Tumor RecurrentLast Updated:November 30, 2018Completed
Condition(s):Non-small Cell Lung Cancer; Squamous Cell Carcinoma of the Head and NeckLast Updated:April 17, 2018Terminated
Condition(s):MDS; Systemic Autoimmune DiseasesLast Updated:October 4, 2022Completed
Condition(s):Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic LeukemiaLast Updated:March 15, 2022Unknown status
Condition(s):Myelodysplastic Syndromes (MDS); Acute Myeloid Leukaemia (AML)Last Updated:February 15, 2016Completed
Condition(s):Relapsed Classic Hodgkin Lymphoma; Refractory Classic Hodgkin LymphomaLast Updated:January 30, 2024Recruiting
Condition(s):Chronic Lymphocytic Leukemia(CLL); Small Lymphocytic LymphomaLast Updated:July 20, 2022Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.